Paradigm Biopharmaceuticals Limited (PBIGF PINK) stock market data APIs
$0.3782
0(0%)
as of March 25, 2025
Paradigm Biopharmaceuticals Limited Financial Data Overview
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Prev. Close
0.3782
Open
0.3782
High
0.3782
Low
0.3782
52 wk Range
0.1147-0.3807
Market Cap
148 M
Shares Outstanding
389 M
Revenue
16 700
Beta
0.923
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Paradigm Biopharmaceuticals Limited data using free add-ons & libraries
Get Paradigm Biopharmaceuticals Limited Fundamental Data
Paradigm Biopharmaceuticals Limited Fundamental data includes:
- Net Revenue: 16 700
- EBITDA: -21 168 364
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: NaN
Get Paradigm Biopharmaceuticals Limited End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Paradigm Biopharmaceuticals Limited News
New
Hope for knee osteoarthritis sufferers with advent of global clinical trial.
Paradigm Biopharma launches clinical trial website to support development program for knee osteoarthritis therapy. MELBOURNE, Australia, May 25, 2023 /PRNewswire/ -- With the launch of a new website ...
Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up
Paradigm Biopharmaceuticals Top-line phase 2 trial data shows disease modifying potential and pain reduction MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Australia’s Paradigm Biopharma...
Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial
KEY HIGHLIGHTS Primary endpoint relating to synovial fluid biomarkers achieved and positive top-line results reported for the PARA_OA_008 phase 2 clinical trial (n=61). Several osteoarthritis (OA) bi...
MPS Clinical Program Update and Paradigm to Present at the International Conference on Lysosomal Diseases
KEY HIGHLIGHTS Paradigm has been invited to present results from the mucopolysaccharidosis (MPS) program, with an oral presentation at the XVII International Conference on Lysosomal Diseases (ICLD 20...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
